Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
Zhang, H., Targher, G., Byrne, C. D., Kim, S. U., Wong, V. W., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C. S., Crespo, J., Gronbaek, H., Yang, W., Eslam, M., Wong, R. J., Machado, M. V., Yu, M., Ghanem, O. M., Okanoue, T., Liu, J., Lee, Y., Xu, X., Pan, Q., Sui, M., Lonardo, A., Yilmaz, Y., Zhu, L., Moreno, C., Miele, L., Lupsor-Platon, M., Zhao, L., Lamasters, T. L., Gish, R. G., Zhang, H., Nedelcu, M., Chan, W. K., Xia, M., Bril, F., Shi, J., Datz, C., Romeo, S., Sun, J., Liu, D., Sookoian, S., Mao, Y., Méndez-Sánchez, N., Wang, X., Pyrsopoulos, N. T., Fan, J., Fouad, Y., Sun, D., Giannini, C., Chai, J., Xia, Z., Jun, D. W., Li, G., Treeprasertsuk, S., Li, Y., Cheung, T. T., Zhang, F., Goh, G. B., Furuhashi, M., Seto, W., Huang, H., Di Sessa, A., Li, Q., Cholongitas, E., Zhang, L., Silveira, T. R., Sebastiani, G., Adams, L. A., Chen, W., Qi, X., Rankovic, I., De Ledinghen, V., Lv, W., Hamaguchi, M., Kassir, R., Müller-Wieland, D., Romero-Gomez, M., Xu, Y., Xu, Y., Chen, S., Kermansaravi, M., Kuchay, M. S., Lefere, S., Parmar, C., Lip, G. Y. H., Liu, C., Åberg, F., Lau, G., George, J., Sarin, S. K., Zhou, J., Zheng, M., A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease, <<HEPATOLOGY INTERNATIONAL>>, 2024; (Jun): N/A-N/A. [doi:10.1007/s12072-024-10702-5] [https://hdl.handle.net/10807/280838]
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Miele, Luca;
2024
Abstract
Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
